Roza Zandi

Roza Zandi

Auto-generated profile, based on publicly available information

Roza Zandi

Department of Hematology and

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in Cellular Signalling
Verified
Journal Article
Closed access
RZRoza Zandi
Roza Zandi
ALAlice Bjerregaard Larsen
Alice Bjerregaard Larsen
PAPeter Andersen
Peter Andersen
MSMarie-Thérése Stockhausen
Marie-Thérése Stockhausen
HPHans Skovgaard Poulsen
Hans Skovgaard Poulsen

19 March 2007 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
MGMichael V. Grandal
Michael V. Grandal
RZRoza Zandi
Roza Zandi
MPMikkel W. Pedersen
Mikkel W. Pedersen
BWBerthe M. Willumsen
Berthe M. Willumsen
BDBo van Deurs
Bo van Deurs
HPHans S. Poulsen
Hans S. Poulsen
EGFRvIII is a mutant variant of the epidermal growth factor receptor (EGFR) found exclusively in various cancer types. EGFRvIII lacks a large part of the extracellular domain and is unable to bind ligands; however, the receptor is constitutively phosphorylated and able to activate downstream signaling pathways. Failure to attenuate signaling by receptor down-regulation could be one of the major mechanisms by which EGFRvIII becomes oncogenic. Using a cell system expressing either EGFR or EGFRvIII with no expression of other EGFR family members and with endogenous levels of key degradation proteins, we have investigated the down-regulation of EGFRvIII and compared it to that of EGFR. We show that, in contrast to EGFR, EGFRvIII is inefficiently degraded. EGFRvIII is internalized, but the internalization rate of the mutated receptor is significantly less than that of unstimulated EGFR. Moreover, internalized EGFRvIII is recycled rather than delivered to lysosomes. EGFRvIII binds the ubiquitin ligase c-Cbl via Grb2, whereas binding via phosphorylated tyrosine residue 1045 seems to be limited. Despite c-Cbl binding, the receptor fails to become effectively ubiquitinylated. Thus, our results suggest that the long lifetime of EGFRvIII is caused by inefficient internalization and impaired sorting to lysosomes due to lack of effective ubiquitinylation.

1 May 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RZRoza Zandi
Roza Zandi
GSGalina Selivanova
Galina Selivanova
CCCamilla Laulund Christensen
Camilla Laulund Christensen
TGThomas Alexander Gerds
Thomas Alexander Gerds
BWBerthe Marie Willumsen
Berthe Marie Willumsen
HPHans Skovgaard Poulsen
Hans Skovgaard Poulsen
Purpose: Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new and efficient treatment modalities. PRIMA-1Met (p53-dependent reactivation of massive apoptosis), also known as APR-246, is a small molecule, which restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Since p53 is mutated in more than 90% of SCLC, we investigated the ability of PRIMA-1Met to induce apoptosis and inhibit tumor growth in SCLC with different p53 mutations. Experimental Design: The therapeutic effect of PRIMA-1Met/APR-246 was studied in SCLC cells in vitro using cell viability assay, fluorescence-activated cell-sorting analysis, p53 knockdown studies, and Western blot analyses. The antitumor potential of PRIMA-1Met/APR-246 was further evaluated in two different SCLC xenograft models. Results: PRIMA-1Met/APR-246 efficiently inhibited the growth of the SCLC cell lines expressing mutant p53 in vitro and induced apoptosis, associated with increased fraction of cells with fragmented DNA, caspase-3 activation, PARP cleavage, Bax and Noxa upregulation and Bcl-2 downregulation in the cells. The growth suppressive effect of PRIMA-1Met/APR-246 was markedly reduced in SCLC cell lines transfected with p53 siRNA, supporting the role of mutant p53 in PRIMA-1Met/APR-246-induced cell death. Moreover, in vivo studies showed significant antitumor effects of PRIMA-1Met after i.v. injection in SCLC mouse models with no apparent toxicity. Conclusion: This study is the first to show the potential use of p53-reactivating molecules such as PRIMA-1Met/APR-246 for the treatment of SCLC. Clin Cancer Res; 17(9); 2830–41. ©2011 AACR.

23 April 2015 in Blood
Verified
Journal Article
Closed access
PDF file
SHSimon Husby
Simon Husby
URUlrik Ralfkiaer
Ulrik Ralfkiaer
CGChristian Garde
Christian Garde
RZRoza Zandi
Roza Zandi
SESara Ek
Sara Ek
KGKirsten Grønbæk
Kirsten Grønbæk
Key Points: miR-18b overexpression identified patients with poor prognosis in 2 large prospective homogenously treated MCL cohorts. miR-18b overexpression adds prognostic information to the MIPI-B prognosticator.

1 April 2009 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
CCCamilla L Christensen
Camilla L Christensen
RZRoza Zandi
Roza Zandi
TGTorben Gjetting
Torben Gjetting
FCFrederik Cramer
Frederik Cramer
HPHans S Poulsen
Hans S Poulsen
Small-cell lung cancer (SCLC) is a highly malignant disease with poor prognosis. Hence, there is great demand for new therapies that can replace or supplement the current available treatment regimes. Gene therapy constitutes a promising strategy and relies on the principle of introducing exogenous DNA into malignant cells causing them to die. Since SCLC is a highly disseminated malignancy, the gene therapeutic agent must be administered systemically, obligating a high level of targeting of tumor tissue and the use of delivery vehicles designed for systemic circulation of the therapeutic DNA. This review describes and discusses the current status of the application of gene therapy in relation to SCLC.

15 November 2011 in Cancer Investigation
Verified
Journal Article
Closed access
PDF file
RZRoza Zandi
Roza Zandi
KXKai Xu
Kai Xu
HPHans S. Poulsen
Hans S. Poulsen
JRJack A. Roth
Jack A. Roth
LJLin Ji
Lin Ji
The candidate tumor suppressor fragile histidine traid (FHIT) is frequently inactivated in small cell lung cancer (SCLC). Mutations in the p53 gene also occur in the majority of SCLC leading to the accumulation of the mutant protein. Here we evaluated the effect of FHIT gene therapy alone or in combination with the mutant p53-reactivating molecule, PRIMA-1Met/APR-246, in SCLC. Overexpression of FHIT by recombinant adenoviral vector (Ad-FHIT)-mediated gene transfer in SCLC cells inhibited their growth by inducing apoptosis and when combined with PRIMA-1Met/APR-246, a synergistic cell growth inhibition was achieved.